Amicus Therapeutics Files 8-K on Financials

Ticker: FOLD · Form: 8-K · Filed: Feb 19, 2025 · CIK: 1178879

Amicus Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyAmicus Therapeutics, Inc. (FOLD)
Form Type8-K
Filed DateFeb 19, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, sec-filing

TL;DR

Amicus Therapeutics dropped an 8-K on financials, check it for the latest numbers.

AI Summary

On February 19, 2025, Amicus Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along with financial statements and exhibits. No specific financial figures or operational details were provided in the excerpt.

Why It Matters

This filing indicates Amicus Therapeutics is providing updates on its financial performance and condition to the SEC, which is crucial for investors to assess the company's health.

Risk Assessment

Risk Level: low — The filing is a standard 8-K reporting operational and financial information, not indicating any immediate negative events.

Key Players & Entities

  • Amicus Therapeutics, Inc. (company) — Registrant
  • February 19, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • 001-33497 (identifier) — Commission File Number
  • 71-0869350 (identifier) — I.R.S. Employer Identification No.
  • 47 Hulfish Street, Princeton, NJ 08542 (address) — Principal Executive Offices
  • 609 - 662-2000 (phone_number) — Registrant's Telephone Number

FAQ

What specific financial results or operational updates are detailed in this 8-K filing?

The provided excerpt indicates the filing concerns 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' but does not contain specific financial figures or operational details.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on February 19, 2025.

What is Amicus Therapeutics, Inc.'s state of incorporation?

Amicus Therapeutics, Inc. is incorporated in Delaware.

What is the Commission File Number for Amicus Therapeutics, Inc.?

The Commission File Number for Amicus Therapeutics, Inc. is 001-33497.

Where are Amicus Therapeutics, Inc.'s principal executive offices located?

Amicus Therapeutics, Inc.'s principal executive offices are located at 47 Hulfish Street, Princeton, NJ 08542.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on February 19, 2025 regarding AMICUS THERAPEUTICS, INC. (FOLD).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.